

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Health Group Limited**  
**中國衛生集團有限公司**

*(Carrying on business in Hong Kong as CHG HS Limited)*

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 673)

**PROFIT WARNING ANNOUNCEMENT**

This announcement is made by China Health Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and Rule 13.09(2)(a) of the Listing Rules.

The board of directors (“**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that based on preliminary review of the unaudited management accounts of the Group, it is expected the Group will record a net loss of approximately HK\$27 million for the six months ended 30 September 2022 as compared to a net loss of approximately HK\$5.2 million for the six months ended 30 September 2021. The expected increase in loss was mainly attributable to fair value change of contingent consideration of approximately HK\$17.2 million arising from issue of consideration shares in respect of the acquisition of a subsidiary of the Company recognised for the six months ended 30 September 2022 (2021: nil). Such fair value change is a non-cash item and does not have an immediate impact on the Group’s cash flows and operations.

The Company is still in the process of finalising the Group’s unaudited interim results for the six months ended 30 September 2022. The information contained in this announcement is only based on the Company’s preliminary review of the unaudited management accounts of the Group, which have not been audited or reviewed by the Company’s auditors. The unaudited interim results for the six months ended 30 September 2022 will be published on 30 November 2022.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China Health Group Limited**  
**Zhang Fan**  
*Chairman of the Board and Executive Director*

Hong Kong, 25 November 2022

*As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Zhang Fan (chairman) and Mr. Chung Ho; three non-executive Directors, namely, Mr. Xing Yong, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.*